# Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05269316/  
OnCo record `nct05269316` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IMP9064 in advanced solid tumours, run by Impact Therapeutics, Inc., now recruiting.

## Summary

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05269316 by Impact Therapeutics, Inc., with 61 participants planned, started 2022-02-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: IMP9064.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05269316
- Phase: 1/2
- Setting: A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors
- Sponsor: Impact Therapeutics, Inc.
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT05269316: https://clinicaltrials.gov/study/NCT05269316

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05269316.json